Key Highlights

  • TCRT shares are trading 1.94% lower at $2.02 on Wednesday, October 28, 2026, from an implied prior close near $2.06 (calculated).
  • Short interest was 818,602 shares for the settlement date of October 15, 2026, up from 9,736 on September 30.
  • That equals about 32.2% of the 2.54 million shares outstanding, with days to cover at 1.00.
  • The financing described on October 13, 2026 totals about $350 million, with Series C preferred shares priced at $1,435.70 each.
  • Conversion of the Series C shares would imply about 358.59 million common shares on an as-converted basis.

Alaunos Therapeutics Move: Why Is the Stock Slipping Even as Short Interest Spikes?

Alaunos Therapeutics (NASDAQ:TCRT) shares are trading 1.94% lower at $2.02 on Wednesday, October 28, 2026. No company announcement dated that day accompanies the move. The shares closed at $2.28 on Friday, October 23, after falling 25.00% that session.

Alaunos is a clinical-stage biotechnology company that has shifted from T-cell receptor oncology toward obesity and cardiopulmonary programs. Its latest catalyst is the acquisition of Velaris Therapeutics, a private developer of therapies for pulmonary arterial hypertension, completed on October 13, 2026 alongside a private placement.

Short Interest Jump: What Could 818,602 Shorted Shares Mean for a Share Base of 2.54 Million?

Short-interest data for the settlement date of October 15, 2026 show 818,602 shares sold short, up 808,866 from 9,736 on September 30. Days to cover were 1.00. Earlier readings were 6,075 shares for September 15 and 5,707 for August 31.

The latest figure is about 32.2% of 2.54 million shares outstanding, and about 68% of the 1.20 million-share float (calculated). A position that large can reflect bearish positioning, possibly tied to dilution from the financing, or mean that any covering would meet thin supply and amplify moves.

The $350 Million Financing: How Large Is the Dilution Against a $5 Million Market Value?

The filing of October 13, 2026 describes a financing of about $350 million, including 243,063 Series C preferred shares at $1,435.70 each and 687,789 common shares at $1.4357 each. Funds affiliated with an investment firm are buying about $100 million. The company says the proceeds should support operations into 2029.

Each Series C share converts into 1,000 common shares once stockholders approve, which implies about 358.59 million common shares on an as-converted basis. At $2.02 and 2.54 million shares, the current market value is about $5.1 million (calculated), a fraction of the financing.

Cash was about $0.354 million at March 31, 2026, and a registered direct offering on September 18, 2026 raised about $1.12 million at $1.46 per share. The trailing twelve-month net loss is about $4.12 million.

Velaris Pipeline and Governance Risks: What Comes With the Deal?

The acquired programs are ActRII-Fc ligand traps, with clinical proof of concept for VLR199 expected in 2028. A name change to Velaris Therapeutics is planned, subject to stockholder approval.

Named risks include the stockholder vote, a planned reverse split with a ratio not yet set, a board in which designees of the principal investor and Velaris would hold four of five seats, and cash settlement rights for Series C holders from six months after issuance.

What to Watch Next: Stockholder Vote, Reverse Split Ratio and the October 30 Short-Interest Date

The stockholder meeting on Series C conversion has no announced date. Readers can follow that date, the reverse split ratio, the October 30, 2026 short-interest settlement and the next quarterly report. Until a dated release explains today's activity, the move rests on trading around the Velaris transaction.